Buy AbbVie Stock Before Q4 Earnings? Here's What to Know

Key Takeaways AbbVie reports Q4 and full-year 2025 earnings Feb. 4, with sales expected above $16.3B and EPS near $2.66.ABBV's newer immunology drugs Skyrizi and Rinvoq are expected to fuel growth as Humira sales keep declining.AbbVie stock trades below industry P/E, driven by a growing pipeline and diversification across franchises.AbbVie (ABBV) is set to report fourth-quarter and full-year 2025 earnings on Feb. 4, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings i ...